Αρχική World News EMA Recommends Extension of Indications for Inotuzumab Ozogamicin World News EMA Recommends Extension of Indications for Inotuzumab Ozogamicin Από Ogkologos - 29 Απριλίου, 2026 235 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of paediatric patients with CD22-positive B cell precursor ALL Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour 26 Νοεμβρίου, 2021 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... 16 Ιανουαρίου, 2023 Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib... 21 Αυγούστου, 2025 Study Says Educational Materials for Chemo Often Require Higher Reading Level... 25 Σεπτεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS FDA Approvals Expand Initial Treatment Options for Multiple Myeloma How I Learned to Advocate for Myself During Cancer: “Your Stories”... Cancer Research UK appoints new Trustees and independent Committee Members FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease